These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17911447)

  • 1. Autoantibody production in anti-TNF-alpha-treated patients.
    Alessandri C; Scrivo R; Spinelli FR; Ceccarelli F; Magrini L; Priori R; Valesini G
    Ann N Y Acad Sci; 2007 Sep; 1110():319-29. PubMed ID: 17911447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of anti-TNF alpha autoantibodies in plasma and from EBV transformed lymphocytes of autoimmune and normal individuals.
    Tsuchiyama L; Wong T; Kieran J; Boyle P; Penza D; Wetzel GD
    Hum Antibodies Hybridomas; 1995; 6(2):73-6. PubMed ID: 7492754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mAbs in nonlupus autoimmune rheumatic disease.
    Whelan BR; Isenberg DA
    Curr Opin Hematol; 2009 Jul; 16(4):280-4. PubMed ID: 19444098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus.
    Rosenau BJ; Schur PH
    J Rheumatol; 2009 Apr; 36(4):753-6. PubMed ID: 19273453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour necrosis factor inhibitors in ankylosing spondylitis.
    Reed MR; Taylor AL
    Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.
    Kontermann RE; Münkel S; Neumeyer J; Müller D; Branschädel M; Scheurich P; Pfizenmaier K
    J Immunother; 2008 Apr; 31(3):225-34. PubMed ID: 18317365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.
    Fromont A; De Seze J; Fleury MC; Maillefert JF; Moreau T
    Cytokine; 2009 Feb; 45(2):55-7. PubMed ID: 19109035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
    Theis VS; Rhodes JM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF-induced lupus.
    Williams EL; Gadola S; Edwards CJ
    Rheumatology (Oxford); 2009 Jul; 48(7):716-20. PubMed ID: 19416947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanisms of production and pathogenesis of autoantibodies].
    Mimori T
    Rinsho Shinkeigaku; 2007 Nov; 47(11):855-7. PubMed ID: 18210817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune diseases induced by TNF-targeted therapies.
    Ramos-Casals M; Brito-Zerón P; Soto MJ; Cuadrado MJ; Khamashta MA
    Best Pract Res Clin Rheumatol; 2008 Oct; 22(5):847-61. PubMed ID: 19028367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological tests in autoimmune rheumatic disease.
    Isenberg DA
    Br J Hosp Med; 1993 Sep 15-Oct 5; 50(6):315-20. PubMed ID: 8242215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of rheumatic diseases in patients with HCV and HIV infection.
    Galeazzi M; Giannitti C; Manganelli S; Benucci M; Scarpato S; Bazzani C; Caporali R; Sebastiani GD
    Autoimmun Rev; 2008 Dec; 8(2):100-3. PubMed ID: 18694850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions.
    Cordiali-Fei P; Trento E; D'Agosto G; Bordignon V; Mussi A; Ardigó M; Mastroianni A; Vento A; Solivetti F; Berardesca E; Ensoli F
    Ann N Y Acad Sci; 2007 Sep; 1110():578-89. PubMed ID: 17911474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression, effective renaturation, and bioactivity of novel single-chain antibodies against TNF-alpha.
    Geng S; Chang H; Qin W; Li Y; Feng J; Shen B
    Prep Biochem Biotechnol; 2008; 38(1):74-86. PubMed ID: 18080912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease.
    Podolsky DK
    Dig Dis; 2009; 27(3):366-9. PubMed ID: 19786766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS).
    Krasenbrink I; Fühlhuber V; Juhasz-Boess I; Stolz E; Hahn A; Kaps M; Hero B; Blaes F
    Neuropediatrics; 2007 Jun; 38(3):114-6. PubMed ID: 17985258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.